- -

Prostate cancer Monte Carlo dose model with (177)Lutetium and (125)Iodine treatments

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Prostate cancer Monte Carlo dose model with (177)Lutetium and (125)Iodine treatments

Mostrar el registro completo del ítem

Juste Vidal, BJ.; Miró Herrero, R.; Morató-Rafet, S.; Verdú Martín, GJ.; Peris, S. (2020). Prostate cancer Monte Carlo dose model with (177)Lutetium and (125)Iodine treatments. Radiation Physics and Chemistry. 174(108908):1-6. https://doi.org/10.1016/j.radphyschem.2020.108908

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/172298

Ficheros en el ítem

Thumbnail
Nombre: JusteMiroMorato-Rafet ...
Tamaño: 446.1Kb
Formato: PDF
Descripción: Versión del Autor.
Abrir/Preview
[Cerrado]
Nombre: 1-s2.0-S0969806X1 ...
Tamaño: 864.8Kb
Formato: PDF
Descripción: Versión editorial
Solicitar una copia al autor

Metadatos del ítem

Título: Prostate cancer Monte Carlo dose model with (177)Lutetium and (125)Iodine treatments
Autor: Juste Vidal, Belen Jeanine Miró Herrero, Rafael Morató-Rafet, Sergio Verdú Martín, Gumersindo Jesús Peris, S.
Entidad UPV: Universitat Politècnica de València. Departamento de Ingeniería Química y Nuclear - Departament d'Enginyeria Química i Nuclear
Fecha difusión:
Resumen:
[EN] Radiation Therapy Planning Systems (RTPS) presently operating in hospitals comprise algorithms founded on deterministic simplifications that do not correctly take into account electron lateral transport in the regions ...[+]
Palabras clave: Radiotherapy treatment planning , Prostate cancer treatment , MCNP6 , Monte Carlo , Brachytherapy , 125I seeds , 177Lu-PSMA
Derechos de uso: Reserva de todos los derechos
Fuente:
Radiation Physics and Chemistry. (issn: 0969-806X )
DOI: 10.1016/j.radphyschem.2020.108908
Editorial:
Elsevier
Versión del editor: https://doi.org/10.1016/j.radphyschem.2020.108908
Código del Proyecto:
info:eu-repo/grantAgreement/GVA//PROMETEO%2F2018%2F035/ES/BIOINGENIERIA DE LAS RADIACIONES IONIZANTES. BIORA/
Tipo: Artículo

References

ancer society. Last Access date: 20 July 2019. Available: https://www.cancer.org/es/.

Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., … Wester, H.-J. (2016). 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. Journal of Nuclear Medicine, 57(7), 1006-1013. doi:10.2967/jnumed.115.168443

Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., … Böning, G. (2015). Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 43(1), 42-51. doi:10.1007/s00259-015-3174-7 [+]
ancer society. Last Access date: 20 July 2019. Available: https://www.cancer.org/es/.

Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., … Wester, H.-J. (2016). 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. Journal of Nuclear Medicine, 57(7), 1006-1013. doi:10.2967/jnumed.115.168443

Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., … Böning, G. (2015). Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 43(1), 42-51. doi:10.1007/s00259-015-3174-7

Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J. (2017). Lutetium177PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Journal of Medical Radiation Sciences, 64(1), 52-60. doi:10.1002/jmrs.227

Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. (2017). 177Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of Nuclear Medicine, 58(8), 1196-1200. doi:10.2967/jnumed.117.191023

Grimm, P., Billiet, I., Bostwick, D., Dicker, A. P., Frank, S., Immerzeel, J., … Langley, S. (2012). Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 109, 22-29. doi:10.1111/j.1464-410x.2011.10827.x

Karaiskos, P., Papagiannis, P., Sakelliou, L., Anagnostopoulos, G., & Baltas, D. (2001). Monte Carlo dosimetry of the selectSeed 125I interstitial brachytherapy seed. Medical Physics, 28(8), 1753-1760. doi:10.1118/1.1384460

Monte Carlo team, “MCNP6TM – User's Manual, Version 6.1.1beta”, Los Álamos National Laboratory, LA-CP-14-00745, Rev. 0, June 2014. Materialise. Mimics Medical 17.0 Reference Guide.

Rahbar, K., Afshar-Oromieh, A., Jadvar, H., & Ahmadzadehfar, H. (2018). PSMA Theranostics: Current Status and Future Directions. Molecular Imaging, 17, 153601211877606. doi:10.1177/1536012118776068

Scarpa, L., Buxbaum, S., Kendler, D., Fink, K., Bektic, J., Gruber, L., … Virgolini, I. (2017). The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. European Journal of Nuclear Medicine and Molecular Imaging, 44(5), 788-800. doi:10.1007/s00259-016-3609-9

Skowronek, J. (2017). Current status of brachytherapy in cancer treatment – short overview. Journal of Contemporary Brachytherapy, 9(6), 581-589. doi:10.5114/jcb.2017.72607

Stock, R. G., Stone, N. N., Cesaretti, J. A., & Rosenstein, B. S. (2006). Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. International Journal of Radiation Oncology*Biology*Physics, 64(2), 527-533. doi:10.1016/j.ijrobp.2005.07.981

[-]

recommendations

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem